455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
415 482 5300
https://www.nektar.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 137
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Howard W. Robin | CEO, President & Director | 2,21M | S.O. | 1953 |
Vivian Wu | Director of Investor Relations & Corporate Affairs | S.O. | S.O. | S.O. |
Mr. Robert Bacci | Senior Vice President of Human Resources & Facilities Operations | S.O. | S.O. | S.O. |
Ms. Jennifer Ruddock | Chief Business Officer | S.O. | S.O. | S.O. |
Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer | S.O. | S.O. | 1966 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
L’ISS Governance QualityScore de Nektar Therapeutics en date du 29 avril 2024 est 6. Les scores principaux sont Audit : 8; Société : 7; Droits des actionnaires : 2; Compensation : 8.